Placebo Inhaled Cannabis

Phase 1

HHannah Harris

Placebo Inhaled Cannabis is one of 5 therapeutic programs targeting Experimental. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

ExperimentalRecruiting

ExperimentalPhase 1

Recruiting

Competition

Competitive Landscape

7 competitors in Experimental

#DrugCompanyPhaseTrials

Active Ethanol

YYale University

Phase 1

1 2

Placebo Inhaled Cannabis

HHannah Harris

Phase 1

1 3

Intravenous Infusion of DMT

UUniversity Hospital, Basel, Switzerland

Phase 1

1 4

Potassium Nitrate

GSK

Preclinical

1 5

Nalbuphine Plus Naloxone

UUniversity of California, San Francisco

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 1Recruiting

Experimental

NCT07434895

Clinical

Trials by Indication[1]

Experimental1 trial

The Effects of Repeated CBD Administration on Cannabis Abuse Liability and Analgesia: A Human Laboratory Study

Recruiting·HHannah Harris·Phase 1·NCT07434895·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Placebo Inhaled Cannabis. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Placebo Inhaled Cannabis. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Hannah Harris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: HHannah Harris

Placebo Inhaled Cannabis

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Experimental1 trial

References

Drug Info

Quick Facts

Related News